Cisplatin vs. Doxorubicin/Cyclophosphamide in BrCa
Status:
Active, not recruiting
Trial end date:
2022-04-01
Target enrollment:
Participant gender:
Summary
This research study is a Phase II clinical trial. Phase II clinical trials test the
effectiveness of an investigational drug, which is cisplatin in this trial, to learn how well
it works in treating a specific cancer. "Investigational" means that cisplatin is still being
studied for use in this setting and that research doctors are trying to find out more about
it-in this case, how effective cisplatin is for treating breast cancer in BRCA mutation
carriers. It also means that the FDA has not yet approved cisplatin for your type of cancer.
Cisplatin has been approved by the FDA for treatment of other cancers.
The purpose of this study is to evaluate cisplatin, a chemotherapy drug that has been shown
to be active in the treatment of women with breast cancer and a BRCA mutation. In this study,
we are comparing cisplatin to the standard chemotherapy, doxorubicin and cyclophosphamide
("AC") that you might receive if you did not participate in this study.